Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.

Abstract excerpt

Many drugs are associated with variable response rates and, of the 1,200 drugs approved for use in the United States, about 15% are associated with adverse drug responses (Jorde, Carey, & Bamshad, 2010c). Often, variable response and risk for toxicity can be explained because of differences in genes and in the proteins encoded by those genes. Single nucleotide polymorphisms (SNPs) responsible for variable...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents, Phytogenic
• Share to Camptothecin
• Share to Cytochrome P-450 CYP2C19